||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Micromet Key Events for 2009

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Key Presentations and Milestones Expected for 2009

Bethesda, MD, January 5, 2009 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
provides an outlook on key events anticipated for the year 2009.

Micromet intends to provide an update on its research and development
programs at the following events:

* April 12 to 16, 2009: Update on several preclinical BiTE
antibodies at the American Association for Cancer Research (AACR)
in Denver, CO;
* April 24, 2009: The company will hold an R&D meeting in New York,
NY for investors and analysts to provide a review of its product
pipeline;
* May 29 to June 5, 2009: Update on a phase 1b clinical trial
combining adecatumumab with docetaxel in late stage metastatic
breast cancer patients at the annual meeting of the American
Society for Clinical Oncology (ASCO) in San Francisco, CA;
* June 4 to 7, 2009: Update on phase 2 clinical trial with
blinatumomab in acute lymphoblastic leukemia (ALL) patients at
the 14th Congress of the European Hematology Association (EHA) in
Berlin, Germany;
* September 20 to 24, 2009: First interim data from a phase 1
clinical trial with MT110, an EpCAM-targeting BiTE antibody, in
patients with metastatic gastro-intestinal and lung cancers at
the joint 15th Congress of the European Cancer Organisation
(ECCO) and 34th Congress of the European Society for Medical
Oncology (ESMO) in Berlin, Germany;
* December 5 to 8, 2009: Update on a phase 2 clinical trial with
blinatumomab in ALL patients and final results from a phase 1
clinical trial in late stage NHL at the annual meeting of the
American Society for Hematology (ASH) in New Orleans, LA.

Additional expected milestones in 2009:

* Adecatumumab, an EpCAM-targeting human monoclonal antibody in
development with Merck-Serono is expected to start a randomized,
controlled, multicenter phase 2 clinical trial in relapsed
colorectal cancer patients after complete resection of liver
metastasis in Q1 2009;
* Blinatumomab, a CD19-targeting BiTE antibody in development with
MedImmune, is expected to start an additional phase 2 clinical
trial in patients with non-Hodgkin's lymphoma (NHL) towards the
end of 2009;
* MT203, a GM-CSF neutralizing human monoclonal antibody in
development with Nycomed for the treatment of chronic
inflammatory and autoimmune diseases, is expected to start a
first clinical phase 1 trial in mid 2009;
* MT228, a glycolipid binding human antibody in development by
Eisai for the treatment of melanoma, is expected to start a first
phase 1 clinical trial in 2009;
* MT293, a humanized monoclonal antibody targeting denatured
collagen, in development by Tracon Pharmaceuticals, Inc. for the
treatment of solid tumors is expected to complete a clinical
phase 1 trial.

Micromet intends to publish results from the research and development
of its programs in peer-reviewed scientific and clinical journals
throughout the year. Micromet also intends to enter into one to two
new collaborations with corporate partners in 2009.

Our next formal company presentation will be at the BIO CEO
Conference February 9 and 10, 2009, in New York, NY.

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or
cell- destroying, T cells against tumor cells, and represent a new
therapeutic approach to cancer therapy. Typically antibodies cannot
engage T cells because T cells lack the appropriate receptors for
binding antibodies. Previous attempts have shown the potential of T
cells to treat cancer, but the therapeutic approaches tested to date
have been hampered by cancer cells' ability to escape recognition by
T cells. The use of BiTE antibodies that are specifically designed to
engage T cells for attacking cancer cells may provide a more
effective anti-tumor approach than conventional monoclonal
antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, Maryland and Munich, Germany. The Company
is developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company uses its
proprietary BiTE® antibody platform to create a new class of
antibodies that specifically activate T cells from the patient's own
immune system to eliminate cancer cells or other disease-related
cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial

(more)

for the treatment of patients with acute lymphoblastic leukemia and a
phase 1 clinical trial for the treatment of patients with
non-Hodgkin's lymphoma. Micromet is developing blinatumomab in
collaboration with MedImmune, a subsidiary of AstraZeneca plc.
Micromet's second BiTE antibody in clinical development is MT110,
which targets the epithelial cell adhesion molecule (EpCAM). The
Company owns all rights to MT 110, which is currently in a phase 1
clinical trial for the treatment of patients with solid tumors. The
Company's third clinical stage antibody is adecatumumab, also known
as MT201, a conventional human monoclonal antibody that targets
EpCAM-expressing solid tumors. Micromet is developing adecatumumab in
collaboration with Merck Serono in a phase 1b clinical trial
evaluating adecatumumab in combination with docetaxel for the
treatment of patients with metastatic breast cancer. Micromet has
licensed a fourth clinical stage antibody, MT293, to TRACON
Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical
trial for the treatment of patients with cancer. The Company's
preclinical programs include MT203, which is being developed in
collaboration with Nycomed. MT203 is a traditional human antibody
neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in the
treatment of inflammatory and autoimmune diseases, such as rheumatoid
arthritis, psoriasis, or multiple sclerosis. Additional BiTE
antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively,
are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
These forward-looking statements include statements regarding the
efficacy and intended utilization of our product candidates and the
development of our BiTE antibody technology. You are urged to
consider statements that include the words "may," "potential," or the
negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, and the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2008, filed with
the SEC on November 6, 2008, as well as other filings by the company
with the SEC.

(more)

Any forward-looking statements are made pursuant to Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and, as such, speak only
as of the date made. Micromet, Inc. undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.


# # #

Contact Information


US Media: European Media:
Andrea tenBroek/Chris Stamm Ludger Wess
(781)-684-0770 +49 (40) 8816 5964
micromet@schwartz-pr.com ludger@akampion.com




US Investors: European Investors:
Susan Noonan Ines-Regina Buth
(212) 966-3650 +49 (30) 2363 2768
susan@sanoonan.com ines@akampion.com



--- End of Message ---

Micromet Inc.
6707 Democracy Boulevard, Suite 505 Bethesda USA

WKN:
A0JMQD; ISIN: US59509C1053;
Listed: Xetra Stars in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.089 Sekunden